Adding isatuximab, an anti-CD38 monoclonal antibody, to bortezomib, lenalidomide, and dexamethasone (VRd) may improve outcomes in transplant-ineligible patients with multiple myeloma. New research ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback